Article
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure.
Clinical lung cancer - 1 Nov 2018
Barbie David A, Spira Alexander, Kelly Karen, Humeniuk Rita, Kawashima Jun, Kong Shengchun, Koczywas Marianna
Abstract excerpt
INTRODUCTION: Specific treatment options are lacking for Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lung cancer (NSCLC) despite treatment advances in other mutation-driven subgroups. PATIENTS AND METHODS: In this study we evaluated the multitargeted Janus kinase/TANK-binding kinase 1 (TBK1) inhibitor momelotinib combined with the mitogen/extracellular signal-related kinase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.